LLatigo Biotherapeutics develops non-opioid pain medicines by discovering and advancing small-molecule drugs, focusing on Nav1.8 channels in peripheral sensory neurons. By blocking Nav1.8, their therapies aim to stop pain at its source, reducing opioid-related risks like addiction and dizziness. The company uses a genetics-informed discovery engine with AI, machine learning, and structure-based design; LTG-001 targets acute pain and LTG-305 targets chronic pain, both in clinical stages. Its differentiated approach centers on genetically validated pain pathways, strong funding, and experienced leadership, with the goal of delivering safe, effective non-opioid analgesics that address pain at its source.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Thousand Oaks, CA
Founded
2018
See people who can refer or advise you
Total Funding
$682.4M
Above
Industry Average
Funded Over
3 Rounds
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Thousand Oaks, CA
Founded
2018
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs